CN114761020A - (5r)-5-羟基雷公藤内酯醇在制备药物中的应用 - Google Patents

(5r)-5-羟基雷公藤内酯醇在制备药物中的应用 Download PDF

Info

Publication number
CN114761020A
CN114761020A CN201880089248.6A CN201880089248A CN114761020A CN 114761020 A CN114761020 A CN 114761020A CN 201880089248 A CN201880089248 A CN 201880089248A CN 114761020 A CN114761020 A CN 114761020A
Authority
CN
China
Prior art keywords
aids
immune
cells
immune activation
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880089248.6A
Other languages
English (en)
Inventor
刘彦君
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dunshan Medical Technology (Shenzhen) Co.,Ltd.
Shanghai Pharmaceuticals Holding Co Ltd
Original Assignee
Shanghai Pharmaceuticals Holding Co Ltd
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Pharmaceuticals Holding Co Ltd, Peking Union Medical College Hospital Chinese Academy of Medical Sciences filed Critical Shanghai Pharmaceuticals Holding Co Ltd
Publication of CN114761020A publication Critical patent/CN114761020A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明公开了(5R)‑5‑羟基雷公藤内酯醇在制备药物中的应用，特别是在制备治疗和/或预防艾滋病异常免疫激活、或者艾滋病异常免疫激活相关的免疫重建不全的药物中的应用。本发明使用(5R)‑5‑羟基雷公藤内酯醇(T8)进行实验后发现，其在艾滋病异常免疫激活、或者艾滋病异常免疫激活相关的免疫重建不全中具有免疫抑制活性，且表现为效率高、毒性低，具有很好的安全治疗指数。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN201880089248.6A 2018-02-13 2018-12-14 (5r)-5-羟基雷公藤内酯醇在制备药物中的应用 Pending CN114761020A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101491494 2018-02-13
CN201810149149 2018-02-13
PCT/CN2018/121201 WO2019157854A1 (zh) 2018-02-13 2018-12-14 (5r)-5-羟基雷公藤内酯醇在制备药物中的应用

Publications (1)

Publication Number Publication Date
CN114761020A true CN114761020A (zh) 2022-07-15

Family

ID=65459291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811532917.0A Withdrawn CN109394771A (zh) 2018-02-13 2018-12-14 （5r）-5-羟基雷公藤内酯醇在制备药物中的应用
CN201880089248.6A Pending CN114761020A (zh) 2018-02-13 2018-12-14 (5r)-5-羟基雷公藤内酯醇在制备药物中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811532917.0A Withdrawn CN109394771A (zh) 2018-02-13 2018-12-14 （5r）-5-羟基雷公藤内酯醇在制备药物中的应用

Country Status (7)

Country Link
US (1) US20210052541A1 (zh)
EP (1) EP3753564A4 (zh)
JP (1) JP2021513554A (zh)
CN (2) CN109394771A (zh)
BR (1) BR112020016473A2 (zh)
WO (1) WO2019157854A1 (zh)
ZA (1) ZA202005671B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821295A (zh) * 2019-04-15 2020-10-27 中国科学院上海药物研究所 (5r)-5-羟基雷公藤内酯醇在制备治疗和/或预防皮肤炎症药物中的应用
CN111202738A (zh) * 2020-02-10 2020-05-29 复旦大学附属中山医院 (5r)-5-羟基雷公藤内酯醇在制备脓毒症治疗药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1511838A (zh) * 2002-12-27 2004-07-14 �й���ѧԺ�Ϻ�ҩ���о��� 雷公藤内酯醇衍生物及其应用
CN103083334A (zh) * 2012-12-20 2013-05-08 李太生 雷公藤多甙在hiv/aids患者中对治疗免疫重建不全及非aids相关疾病与免疫重建不全的新用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1511838A (zh) * 2002-12-27 2004-07-14 �й���ѧԺ�Ϻ�ҩ���о��� 雷公藤内酯醇衍生物及其应用
CN103083334A (zh) * 2012-12-20 2013-05-08 李太生 雷公藤多甙在hiv/aids患者中对治疗免疫重建不全及非aids相关疾病与免疫重建不全的新用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHOU, R 等.: "Inhibition of inducible nitric-oxide synthase expression by (5R)-5- hydroxytriptolide in interferon-γ- and bacterial lipopolysaccharide-stimulated macrophages.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS., vol. 316, no. 1, pages 121 - 128, XP055631810, DOI: 10.1124/jpet.105.093179 *

Also Published As

Publication number Publication date
US20210052541A1 (en) 2021-02-25
CN109394771A (zh) 2019-03-01
WO2019157854A1 (zh) 2019-08-22
EP3753564A4 (en) 2021-11-10
BR112020016473A2 (pt) 2020-12-15
JP2021513554A (ja) 2021-05-27
EP3753564A1 (en) 2020-12-23
ZA202005671B (en) 2021-09-29

Similar Documents

Publication Publication Date Title
US20190276803A1 (en) Method of culturing immune cells, kit for thereof, immune cell cultured medium obtained by same method, cosmetic composition and pharmaceutical composition comprising thereof
KR100196368B1 (ko) 아폽토시스 조정제
JP2007529544A (ja) ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩
JP2002505337A (ja) アシル化ベツリンおよびジヒドロベツリンの誘導体、その調製物、およびそれらの使用
Shi et al. Tremella Polysaccharides attenuated sepsis through inhibiting abnormal CD4+ CD25high regulatory T cells in mice
de Carvalho et al. The immunoregulatory function of polyphenols: implications in cancer immunity
CN114761020A (zh) (5r)-5-羟基雷公藤内酯醇在制备药物中的应用
JP2020503343A (ja) 治療剤、ならびに腫瘍および／またはがんの治療のための薬物のためのその使用
WO2008088806A1 (en) Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
TWI351961B (en) Pharmaceutical composition for enhancing immunity,
Zhou et al. Up-regulation of IL-10 expression in dendritic cells is involved in Trichosanthin-induced immunosuppression
WO2016127848A1 (zh) 绿原酸在制备预防和治疗原发性皮肤t细胞淋巴癌的药物中的用途
KR101633432B1 (ko) 감마 허피스바이러스 감염의 개선 및 치료에 사용하기 위한 아까시나무 추출물의 용도
US20170340689A1 (en) Titrated extracts of cynara scolymus for use in the treatment of mesothelioma
CN107132357B (zh) 一种逆转乙型肝炎病毒慢性感染的抗Tim-3抗体和α-galcer的组合及应用
Zhang et al. Triptolide promotes generation of FoxP3+ T regulatory cells in rats
AU2021413899A1 (en) Monoclonal antibody against human mac-1 and uses thereof
KR20120095320A (ko) 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물
CN108853129B (zh) 升麻素苷在制备髓源性抑制细胞抑制药物中的应用
US20240307346A1 (en) Method for treating or preventing a disease of incomplete immune reconstitution in aids using (5r)-5-hydroxytriptolide
CN112023048A (zh) 一种对阿糖胞苷耐药的稳转重组b淋巴细胞白血病细胞系的构建方法及其应用
CN116003258B (zh) 12-o-辛酰基-佛波醇酯类衍生物及制备方法和应用
JP3817273B2 (ja) 免疫抑制治療、抗ガン治療および抗ウイルス治療用の薬学的組成物
JPWO2020026953A1 (ja) 抗ヘルペスウイルス剤
CN116785417B (zh) 芦荟苷与her2-car-t细胞联合制备治疗骨肉瘤的药物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20221117

Address after: 518000 no.2938, block B, Tianxia International Center, No.8 Taoyuan Road, dawangshan community, Nantou street, Nanshan District, Shenzhen City, Guangdong Province

Applicant after: Dunshan Medical Technology (Shenzhen) Co.,Ltd.

Applicant after: SHANGHAI PHARMACEUTICALS HOLDING Co.,Ltd.

Address before: 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing

Applicant before: PEKING UNION MEDICAL COLLEGE Hospital

Applicant before: SHANGHAI PHARMACEUTICALS HOLDING Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081356

Country of ref document: HK